fullsquare

Who does this appeal to? It's nonsense.

the fake nerds of silicon valley of course

on reddit, the website plays you

have rules never clearly explained, get banned pretty much immediately. a taste of real reddit experience™ even that i've never got banned sitewide (only on r/conservative) i guess you win if you touch grass or quit

death of millions for profit - solid business practice, congratulations and see you again at next shareholder meeting

that's just internet dementia

has he? where?

Derek Lowe casually points to Yarvin and Thiel in his writeup on how trumpists are destroying american science, in part 7 specifically. nrx have fully broke containment

Derek Lowe has seen it coming years ago https://www.science.org/content/blog-post/lecanemab-and-alzheimer-s-more-data

But let’s stipulate that the result is real, for the sake of argument. That takes us into the very contentious question of real-world utility. As the NEJM paper says, “A definition of clinically meaningful effects in the primary end point of the CDR-SB score has not been established”. Clinicians are already disagreeing over whether the difference between lecanemab and placebo is something that would even be noticeable. That last link features a quote of Madhav Thambisetty, a neurologist at the National Institute on Aging: “From the perspective of a physician caring for Alzheimer’s patients, the difference between lecanemab and placebo is well below what is considered to be a clinically meaningful treatment effect”. This is not an uncommon take.

And that leads to question 3. A constant problem with these anti-amyloid antibody ideas is the complication of brain edema, an inflammation response that can be serious trouble. The term of the art is “amyloid-related imaging abnormalities with edema or effusions”, ARIA-E. This latest trial kept a constant watch for this, as well it should have, and any such trial also has to keep in mind the possibility of “functional unblinding” as any incidents develop. ARIA-E was noted in 0.8% of the treatment group (and in none of the placebo patients, naturally). Overall, adverse events that were enough to lead to patient discontinuation in the trial occurred in 6.9% of the treatment group and 2.9% of the placebo group. Most seriously, two patients in the treatment group have died from what could well be treatment-related vascular issues

There was also earlier anti-amyloid antibody that got approved despite showing no benefit at all https://www.science.org/content/blog-post/they-don-t-know